Cornerstone Capital Management Holdings LLC. Has $15.26 Million Stake in Allergan PLC. (AGN)
Cornerstone Capital Management Holdings LLC. decreased its stake in Allergan PLC. (NYSE:AGN) by 12.6% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 63,895 shares of the company’s stock after selling 9,240 shares during the period. Cornerstone Capital Management Holdings LLC.’s holdings in Allergan PLC. were worth $15,264,000 as of its most recent SEC filing.
A number of other large investors have also added to or reduced their stakes in the company. Norges Bank purchased a new position in shares of Allergan PLC. during the fourth quarter valued at $682,333,000. Appaloosa LP increased its position in shares of Allergan PLC. by 249.8% in the fourth quarter. Appaloosa LP now owns 4,261,406 shares of the company’s stock valued at $894,938,000 after buying an additional 3,043,097 shares during the period. Baupost Group LLC MA increased its position in shares of Allergan PLC. by 71.5% in the fourth quarter. Baupost Group LLC MA now owns 3,432,603 shares of the company’s stock valued at $720,881,000 after buying an additional 1,430,625 shares during the period. Iridian Asset Management LLC CT increased its position in shares of Allergan PLC. by 141.3% in the first quarter. Iridian Asset Management LLC CT now owns 1,283,833 shares of the company’s stock valued at $306,733,000 after buying an additional 751,848 shares during the period. Finally, Janus Capital Management LLC increased its position in shares of Allergan PLC. by 20.5% in the fourth quarter. Janus Capital Management LLC now owns 3,897,873 shares of the company’s stock valued at $818,699,000 after buying an additional 663,390 shares during the period. Institutional investors own 84.66% of the company’s stock.
Allergan PLC. (NYSE:AGN) traded up 0.07% during mid-day trading on Thursday, hitting $250.36. 3,414,569 shares of the company were exchanged. Allergan PLC. has a 12-month low of $184.50 and a 12-month high of $256.80. The company’s market cap is $84.09 billion. The stock’s 50 day moving average is $245.21 and its 200-day moving average is $237.12.
Allergan PLC. (NYSE:AGN) last issued its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.95 by $0.07. The company had revenue of $4.01 billion during the quarter, compared to analysts’ expectations of $3.95 billion. Allergan PLC. had a return on equity of 7.29% and a net margin of 82.42%. The business’s revenue was up 8.8% on a year-over-year basis. During the same period last year, the business earned $3.35 earnings per share. Equities research analysts predict that Allergan PLC. will post $16.08 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 15th. Shareholders of record on Friday, August 18th will be issued a dividend of $0.70 per share. The ex-dividend date of this dividend is Wednesday, August 16th. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.12%. Allergan PLC.’s payout ratio is presently 9.63%.
Several research analysts have recently weighed in on AGN shares. Royal Bank Of Canada set a $279.00 target price on shares of Allergan PLC. and gave the company a “buy” rating in a research note on Wednesday, April 12th. Citigroup Inc. restated a “focus list” rating and issued a $261.27 target price (up from $184.50) on shares of Allergan PLC. in a research note on Friday, April 21st. Goldman Sachs Group, Inc. (The) downgraded shares of Allergan PLC. from a “buy” rating to a “neutral” rating and set a $262.00 target price for the company. in a research note on Wednesday, May 10th. UBS AG restated a “buy” rating and issued a $275.00 target price on shares of Allergan PLC. in a research note on Monday, May 15th. Finally, Sanford C. Bernstein restated an “outperform” rating on shares of Allergan PLC. in a research note on Thursday, May 25th. Seven research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $273.99.
In other Allergan PLC. news, Director Nesli Basgoz sold 1,889 shares of Allergan PLC. stock in a transaction on Thursday, May 18th. The stock was sold at an average price of $220.45, for a total transaction of $416,430.05. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.36% of the stock is currently owned by company insiders.
Allergan PLC. Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Stock Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related stocks with our FREE daily email newsletter.